This bill directs the American Battle Monuments Commission to correct historical errors by identifying Jewish World War I and II veterans buried overseas under incorrect Christian markers (Latin crosses) and replacing them with appropriate markers. It establishes a 10-year program to contact families of affected veterans, with the Commission funding the effort at $500,000 annually through nonprofit contracts. The program specifically targets veterans buried in foreign U.S. military cemeteries with markers indicating non-Jewish faith, addressing a documented mistake affecting approximately 900 Jewish servicemembers. This directly affects Jewish veterans' families by honoring their heritage and correcting past burial inaccuracies.
SRES 536 is a non-binding Senate resolution designating December 2, 2025, as "World Nuclear Energy Day." It commemorates nuclear energy's role in clean power generation, highlighting historical milestones like the first nuclear chain reaction (1942) and the first commercial nuclear plant (1957). The resolution celebrates nuclear energy's contributions to U.S. electricity (18% of generation, 43% carbon-free), job creation (over 70,000 direct jobs), and national security, without creating new laws or affecting any group. It serves as a symbolic recognition of the industry's achievements.
This bill amends the Natural Gas Act to give the Federal Energy Regulatory Commission (FERC) exclusive authority to approve U.S. LNG export terminal projects, requiring FERC to deem such exports consistent with the public interest. It directly affects natural gas companies seeking to build or expand export facilities and streamlines FERC's review process by removing prior requirements for interagency coordination. The bill clarifies that FERC's decisions won't override existing sanctions laws, including restrictions on trade with countries designated as state sponsors of terrorism under current law. This change aims to accelerate domestic LNG export projects while maintaining legal safeguards for national security and foreign policy.
SRES 531 is a non-binding Senate resolution celebrating the 50th anniversary of the Individuals with Disabilities Education Act (IDEA) on November 29, 2025. It recognizes IDEA's historical role in guaranteeing children with disabilities access to free appropriate public education in inclusive settings, transforming educational opportunities for millions. The resolution honors students, families, educators, and advocates who advanced IDEA's principles since its 1975 enactment. It does not create new policy but formally acknowledges the law's enduring impact on educational equity.
HR 2965, the Small Business Regulatory Reduction Act of 2025, requires the Small Business Administration (SBA) to ensure that the cost to small businesses from federal agency rulemaking (including new rules, modifications, or repeals) does not exceed zero starting in fiscal year 2026. It mandates the SBA’s Office of Advocacy to annually report to Congress on all federal rules affecting small businesses, broken down by the issuing agency. The bill applies to all federal agencies, not just the SBA, and focuses on controlling regulatory costs for small businesses. No new funding is provided to implement these requirements.
HR 1049 requires public schools receiving federal education funds to disclose information about foreign-funded activities to parents. Schools must provide parents with access to classroom materials or teacher training paid for by foreign governments or entities, and disclose details about foreign donations, contracts, or staff paid with foreign funds upon written request. Parents can request this information within 30 days, and schools must post annual summaries online. The bill aims to increase transparency about foreign influence in K-12 education, directly affecting parents of students in participating schools.
This bill allows the Social Security Administration to reissue a new Social Security number to children under 14 if their card was lost or stolen, after a parent or guardian provides sworn evidence of the incident. It amends the Social Security Act to create a formal process for reissuing numbers when a child’s card was compromised during transmission. The Commissioner must issue a new number and document the loss/theft reason in the child’s records. This directly affects minors under 14 whose Social Security cards were lost or stolen before they turned 14.
The Claiming Age Clarity Act (HR 5284) requires the Social Security Administration to update its official terminology by January 1, 2027. It directs the replacement of specific terms: "early eligibility age" becomes "minimum monthly benefit age," "full retirement age" and "normal retirement age" become "standard monthly benefit age," and "delayed retirement credit" is eliminated, with "maximum monthly benefit age" used instead of age 70 references. This change applies to all Social Security Administration rules, regulations, guidance, and materials, both online and in print, affecting how the agency communicates retirement benefit rules to the public.
HR 4549, the Office of Rural Affairs Enhancement Act, amends the Small Business Administration's structure to better serve rural small businesses. It requires the Office's Assistant Administrator to have specific rural business expertise and mandates new outreach activities, including regional webinars and events for rural small business owners. The bill also adds annual reporting requirements for the SBA, detailing the Office's budget, staff, outreach events, and analysis of lending programs targeting rural businesses. These changes directly affect rural small business concerns (defined as those in rural areas per SBA rules) and the SBA's operational approach to their support. The legislation focuses on strengthening the Office's capacity to connect rural businesses with federal resources.
This bill reduces the required aggregate market value of voting and non-voting common equity shares for an issuer of securities to qualify as a well-known seasoned issuer. A well-known seasoned issuer is allowed to make expedited public offerings of securities through automatic shelf registrations.
HR 4313, the Hospital Inpatient Services Modernization Act, extends Medicare's waiver allowing acute hospital care at home until 2030 (previously expiring in 2025). It requires the Secretary of Health and Human Services to conduct a detailed study by September 2028 comparing home-based hospital care to traditional inpatient care. The study must analyze quality metrics (like readmission rates and patient outcomes), costs, staffing patterns, and patient demographics - including racial, ethnic, and socioeconomic data - across participating and non-participating hospitals. This bill directly affects Medicare beneficiaries receiving home-based care and hospitals operating under the waiver program.
Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
